Myovant and Pfizer’s path to securing a second nod for Myfembree gets hazy — and investors react quickly

Myovant was on tap for a May 6 decision on a supplemental NDA for its three-in-one pill Myfembree, aiming to treat moderate to severe pain …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

My­ovant and Pfiz­er’s path to se­cur­ing a sec­ond nod for Myfem­bree gets hazy — and in­vestors re­act quick­ly